BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 991731)

  • 1. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
    Mertz DP
    Fortschr Med; 1983 May; 101(18):851-3. PubMed ID: 6862346
    [No Abstract]   [Full Text] [Related]  

  • 5. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F; Neuwirth R; Berg G
    Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Normurat (benzbromaron) in the treatment of gout].
    Bosmanský K; Trnavský K
    Z Rheumatol; 1979; 38(9-10):342-8. PubMed ID: 525067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
    Fortschr Med; 1979 May; 97(17):835-6. PubMed ID: 437646
    [No Abstract]   [Full Text] [Related]  

  • 11. [Uric-acid reduction with high allopurinol dosages (author's transl)].
    Mertz DP; Loewer H
    Dtsch Med Wochenschr; 1979 Mar; 104(9):324-5. PubMed ID: 761542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and tolerance of long-term uricosuric treatment].
    Berg H
    Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F
    Fortschr Med; 1983 May; 101(20):953-9. PubMed ID: 6873850
    [No Abstract]   [Full Text] [Related]  

  • 14. [Allomaron in hyperuricemia and gout].
    Barsom S
    ZFA (Stuttgart); 1979 Aug; 55(24):1336-40. PubMed ID: 539082
    [No Abstract]   [Full Text] [Related]  

  • 15. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
    Mertz DP; Borner K
    Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effect of benzbromaron in gout patients with limited kidney function].
    Kuzmits R; Bresnik W; Müller MM
    Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect on uric acid and other laboratory parameters. A long-term study].
    Dorn M
    ZFA (Stuttgart); 1982 Feb; 58(5):296-300. PubMed ID: 7043937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.